CL2022002395A1 - Compuestos para su uso en afecciones inflamatorias - Google Patents

Compuestos para su uso en afecciones inflamatorias

Info

Publication number
CL2022002395A1
CL2022002395A1 CL2022002395A CL2022002395A CL2022002395A1 CL 2022002395 A1 CL2022002395 A1 CL 2022002395A1 CL 2022002395 A CL2022002395 A CL 2022002395A CL 2022002395 A CL2022002395 A CL 2022002395A CL 2022002395 A1 CL2022002395 A1 CL 2022002395A1
Authority
CL
Chile
Prior art keywords
compounds
inflammatory conditions
inflammation
relates
toll
Prior art date
Application number
CL2022002395A
Other languages
English (en)
Inventor
Avilés Marín Pablo
Losada González Alejandro
María Fernández Sousa-Faro José
Fudio Muñoz Salvador
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of CL2022002395A1 publication Critical patent/CL2022002395A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al uso de compuestos en el tratamiento de la inflamación, preferentemente la inflamación asociada con la activación de receptores de tipo Toll. La invención también se refiere al uso de compuestos para tratar la inflamación inducida por patógenos.
CL2022002395A 2020-03-02 2022-09-02 Compuestos para su uso en afecciones inflamatorias CL2022002395A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382339 2020-04-27
EP20382815 2020-09-16
EP20382816 2020-09-16
EP21382059 2021-01-25

Publications (1)

Publication Number Publication Date
CL2022002395A1 true CL2022002395A1 (es) 2023-06-30

Family

ID=74732953

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022002396A CL2022002396A1 (es) 2020-03-02 2022-09-02 Compuestos para su uso en infecciones víricas
CL2022002395A CL2022002395A1 (es) 2020-03-02 2022-09-02 Compuestos para su uso en afecciones inflamatorias

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2022002396A CL2022002396A1 (es) 2020-03-02 2022-09-02 Compuestos para su uso en infecciones víricas

Country Status (17)

Country Link
US (2) US20230295236A1 (es)
EP (2) EP4114435A1 (es)
JP (2) JP2023517535A (es)
KR (2) KR20220151643A (es)
CN (2) CN115666616A (es)
AU (2) AU2021232535A1 (es)
BR (2) BR112022016604A2 (es)
CA (2) CA3169544A1 (es)
CL (2) CL2022002396A1 (es)
CO (2) CO2022014031A2 (es)
IL (2) IL296069A (es)
MX (2) MX2022010926A (es)
PE (2) PE20230606A1 (es)
PY (2) PY2117308A (es)
TW (2) TW202144381A (es)
UY (2) UY39109A (es)
WO (2) WO2021175831A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021175826A1 (en) * 2020-03-02 2021-09-10 Pharma Mar, S.A. Compounds for use in the treatment of coronavirus infection
CA3169544A1 (en) * 2020-03-02 2021-09-10 Pablo Aviles Marin Compounds for use in inflammatory conditions
JP2023517194A (ja) * 2020-03-02 2023-04-24 ファルマ、マール、ソシエダード、アノニマ コロナウイルス感染の処置における組合せに使用するためのｐｌｄ
WO2024165764A1 (en) * 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections
CN117285611B (zh) * 2023-11-24 2024-02-09 中国海洋大学 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
CN1297352A (zh) * 1998-04-14 2001-05-30 哈桑·朱马 有机磷化合物在治疗和预防性治疗感染中的应用
ES2272462T3 (es) 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
CA2430897C (en) * 2000-12-07 2010-11-16 Universiteit Utrecht Holding B.V. Liposomal composition comprising water-soluble corticosteroids for the treatment of inflammatory disorders
EP1596823A2 (en) * 2003-02-21 2005-11-23 Sun Pharmaceuticals Industries Ltd. A stable ophthalmic composition
CA2519234A1 (en) 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
CN101389347B (zh) * 2006-02-28 2013-03-27 法马马有限公司 提高的抗肿瘤治疗
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
SG10201501980SA (en) * 2009-12-15 2015-05-28 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
US20120040033A1 (en) * 2010-08-10 2012-02-16 Ernest Timothy Armstrong Anti-infective mangrove extract against viruses, bacteria and fungi
GB201316524D0 (en) * 2013-09-17 2013-10-30 Medical Res Council Biomarkers
WO2016044095A1 (en) * 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
US11771739B2 (en) * 2017-06-16 2023-10-03 Vanderbilt University Methods and compositions for treating microbial inflammation
CA3169544A1 (en) * 2020-03-02 2021-09-10 Pablo Aviles Marin Compounds for use in inflammatory conditions

Also Published As

Publication number Publication date
EP4114433A2 (en) 2023-01-11
US20230295236A1 (en) 2023-09-21
PY2117301A (es) 2022-08-09
IL296068A (en) 2022-11-01
TW202146038A (zh) 2021-12-16
AU2021232535A1 (en) 2022-10-06
PE20230606A1 (es) 2023-04-10
MX2022010921A (es) 2022-09-29
KR20220151643A (ko) 2022-11-15
CN115461067A (zh) 2022-12-09
UY39109A (es) 2021-09-30
CA3169544A1 (en) 2021-09-10
CN115666616A (zh) 2023-01-31
TW202144381A (zh) 2021-12-01
JP2023517536A (ja) 2023-04-26
US20230159594A1 (en) 2023-05-25
TWI908772B (zh) 2025-12-21
EP4114435A1 (en) 2023-01-11
KR20220150350A (ko) 2022-11-10
WO2021175831A2 (en) 2021-09-10
IL296069A (en) 2022-11-01
BR112022016604A2 (pt) 2022-10-11
JP2023517535A (ja) 2023-04-26
BR112022016675A2 (pt) 2022-10-11
PY2117308A (es) 2022-08-09
CL2022002396A1 (es) 2023-06-30
WO2021175831A3 (en) 2021-10-14
AU2021231197A1 (en) 2022-10-06
PE20230412A1 (es) 2023-03-07
MX2022010926A (es) 2022-09-29
UY39110A (es) 2021-09-30
CA3169540A1 (en) 2021-09-10
CO2022014031A2 (es) 2022-10-21
WO2021175857A1 (en) 2021-09-10
CO2022014093A2 (es) 2022-11-18

Similar Documents

Publication Publication Date Title
CL2022002395A1 (es) Compuestos para su uso en afecciones inflamatorias
CO2022002759A2 (es) Antagonistas de hpk1 y sus usos
CL2018000128A1 (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
ECSP19031545A (es) Composiciones de células t con car anti-bcma
GT201300128A (es) Variantes de fc silenciosas de los anticuerpos anti-cd40
DOP2013000036A (es) Derivados de ciclobutano como inhibidores de jak
HN2008001464A (es) Formulaciones para administrcion parenteral de compuestos y sus usos
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
MX2011007647A (es) Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
CR20110069A (es) Agentes de fijacion al receptor notch1 y metodos para el uso de los mismos
CL2018000413A1 (es) Composición y productos que comprenden células senescentes para su uso en la regeneración de tejidos
DOP2011000217A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
NI201900075A (es) Compuesto moduladores del receptor de hidrocarburos de arilo (ahr)
CU20140073A7 (es) Composiciones y métodos para anticuerpos que actúan sobre el factor p
CR20190392A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
MX2018005589A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CR20150496A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
MX2019000428A (es) Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori.
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
CO6620038A2 (es) Compuestos de adenosina y su uso
MX365438B (es) Compuestos de tipo 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores mglur2.
CL2022002589A1 (es) Tratamiento de trastornos respiratorios